Apalutamide (Erleada™) 60 mg or 240 mg tablets trials for Prostate cancer

All Apalutamide (Erleada™) 60 mg or 240 mg tablets trials · All Prostate cancer trials

Phase breakdown

Recruiting trials studying Apalutamide (Erleada™) 60 mg or 240 mg tablets for Prostate cancer

• PSA Biochemical Response as Prognostic Factor in Metastatic Castration-Sensitive Prostate Cancer
  NCT06652607 · Phase: Not specified · Ages: 18 Years and older · Sex: Male · 1 location
• Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial.
  NCT07333066 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 56 locations
• Study of ORIC-944 in Patients With Metastatic Prostate Cancer
  NCT05413421 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 27 locations

Common questions

How many trials study Apalutamide (Erleada™) 60 mg or 240 mg tablets for Prostate cancer?

3 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.